![Jean Combalbert](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Jean Combalbert
Chief Executive Officer at Ogeda SA
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Alain Parthoens | M | 64 |
Epics Therapeutics SA
![]() Epics Therapeutics SA Miscellaneous Commercial ServicesCommercial Services EPICS Therapeutics SA engages in the development of therapeutic solutions for cancer. The company was founded by Jean Combalbert, Alain Parthoens and Francois Fuks on February 20, 2018 and is headquartered in Charleroi, Belgium.
Ogeda SA
![]() Ogeda SA Pharmaceuticals: MajorHealth Technology Ogeda SA discovers and develops small molecule drugs. It develops NK3 antagonists for the treatment of hormone-dependent pathologies in the field of Women's Health. The company was founded in 1994 and is headquartered in Gosselies, Spain. | 6 years |
Lena Elisabeth Svanberg | M | 63 |
Epics Therapeutics SA
![]() Epics Therapeutics SA Miscellaneous Commercial ServicesCommercial Services EPICS Therapeutics SA engages in the development of therapeutic solutions for cancer. The company was founded by Jean Combalbert, Alain Parthoens and Francois Fuks on February 20, 2018 and is headquartered in Charleroi, Belgium. | 3 years |
Lawrence Steinman | M | 76 | 4 years | |
Roy Ervin Twyman | M | 68 |
Syndesi Therapeutics SA
![]() Syndesi Therapeutics SA Miscellaneous Commercial ServicesCommercial Services Syndesi Therapeutics SA develops novel therapeutics for cognitive impairment which includes Alzheimer’s disease, dementias, and cognitive impairment associated with schizophrenia. The company is headquartered in Louvain-la-Neuve, Belgium. | - |
Francois Fuks | M | - |
Epics Therapeutics SA
![]() Epics Therapeutics SA Miscellaneous Commercial ServicesCommercial Services EPICS Therapeutics SA engages in the development of therapeutic solutions for cancer. The company was founded by Jean Combalbert, Alain Parthoens and Francois Fuks on February 20, 2018 and is headquartered in Charleroi, Belgium. | 6 years |
Graeme Fraser | M | - |
Ogeda SA
![]() Ogeda SA Pharmaceuticals: MajorHealth Technology Ogeda SA discovers and develops small molecule drugs. It develops NK3 antagonists for the treatment of hormone-dependent pathologies in the field of Women's Health. The company was founded in 1994 and is headquartered in Gosselies, Spain. | - |
Emmanuel Lacroix | M | - |
Syndesi Therapeutics SA
![]() Syndesi Therapeutics SA Miscellaneous Commercial ServicesCommercial Services Syndesi Therapeutics SA develops novel therapeutics for cognitive impairment which includes Alzheimer’s disease, dementias, and cognitive impairment associated with schizophrenia. The company is headquartered in Louvain-la-Neuve, Belgium. | - |
Maeve Duffy | M | - |
Syndesi Therapeutics SA
![]() Syndesi Therapeutics SA Miscellaneous Commercial ServicesCommercial Services Syndesi Therapeutics SA develops novel therapeutics for cognitive impairment which includes Alzheimer’s disease, dementias, and cognitive impairment associated with schizophrenia. The company is headquartered in Louvain-la-Neuve, Belgium. | - |
Morten Graugaard Døssing | M | - |
Syndesi Therapeutics SA
![]() Syndesi Therapeutics SA Miscellaneous Commercial ServicesCommercial Services Syndesi Therapeutics SA develops novel therapeutics for cognitive impairment which includes Alzheimer’s disease, dementias, and cognitive impairment associated with schizophrenia. The company is headquartered in Louvain-la-Neuve, Belgium. | - |
Steven Ramael | M | - |
Ogeda SA
![]() Ogeda SA Pharmaceuticals: MajorHealth Technology Ogeda SA discovers and develops small molecule drugs. It develops NK3 antagonists for the treatment of hormone-dependent pathologies in the field of Women's Health. The company was founded in 1994 and is headquartered in Gosselies, Spain. | - |
Hamid Hoveyda | M | - |
Ogeda SA
![]() Ogeda SA Pharmaceuticals: MajorHealth Technology Ogeda SA discovers and develops small molecule drugs. It develops NK3 antagonists for the treatment of hormone-dependent pathologies in the field of Women's Health. The company was founded in 1994 and is headquartered in Gosselies, Spain. | 17 years |
Alexandra Tolia | M | - |
Epics Therapeutics SA
![]() Epics Therapeutics SA Miscellaneous Commercial ServicesCommercial Services EPICS Therapeutics SA engages in the development of therapeutic solutions for cancer. The company was founded by Jean Combalbert, Alain Parthoens and Francois Fuks on February 20, 2018 and is headquartered in Charleroi, Belgium. | - |
Philippe Monteyne | M | - |
Ogeda SA
![]() Ogeda SA Pharmaceuticals: MajorHealth Technology Ogeda SA discovers and develops small molecule drugs. It develops NK3 antagonists for the treatment of hormone-dependent pathologies in the field of Women's Health. The company was founded in 1994 and is headquartered in Gosselies, Spain. | - |
Jean-Paul Prieels | M | 78 |
Ogeda SA
![]() Ogeda SA Pharmaceuticals: MajorHealth Technology Ogeda SA discovers and develops small molecule drugs. It develops NK3 antagonists for the treatment of hormone-dependent pathologies in the field of Women's Health. The company was founded in 1994 and is headquartered in Gosselies, Spain. | - |
Yves Joseph Ribeill | M | 64 |
Ogeda SA
![]() Ogeda SA Pharmaceuticals: MajorHealth Technology Ogeda SA discovers and develops small molecule drugs. It develops NK3 antagonists for the treatment of hormone-dependent pathologies in the field of Women's Health. The company was founded in 1994 and is headquartered in Gosselies, Spain. | - |
Vincent Lannoy | M | - |
Ogeda SA
![]() Ogeda SA Pharmaceuticals: MajorHealth Technology Ogeda SA discovers and develops small molecule drugs. It develops NK3 antagonists for the treatment of hormone-dependent pathologies in the field of Women's Health. The company was founded in 1994 and is headquartered in Gosselies, Spain. | 24 years |
Philippe Degive | M | - |
Ogeda SA
![]() Ogeda SA Pharmaceuticals: MajorHealth Technology Ogeda SA discovers and develops small molecule drugs. It develops NK3 antagonists for the treatment of hormone-dependent pathologies in the field of Women's Health. The company was founded in 1994 and is headquartered in Gosselies, Spain. | - |
Fiona MacLaughlin | M | - |
Syndesi Therapeutics SA
![]() Syndesi Therapeutics SA Miscellaneous Commercial ServicesCommercial Services Syndesi Therapeutics SA develops novel therapeutics for cognitive impairment which includes Alzheimer’s disease, dementias, and cognitive impairment associated with schizophrenia. The company is headquartered in Louvain-la-Neuve, Belgium. | 4 years |
Michel Allé | M | 74 |
Ogeda SA
![]() Ogeda SA Pharmaceuticals: MajorHealth Technology Ogeda SA discovers and develops small molecule drugs. It develops NK3 antagonists for the treatment of hormone-dependent pathologies in the field of Women's Health. The company was founded in 1994 and is headquartered in Gosselies, Spain. | - |
Al Gray | M | - |
Ogeda SA
![]() Ogeda SA Pharmaceuticals: MajorHealth Technology Ogeda SA discovers and develops small molecule drugs. It develops NK3 antagonists for the treatment of hormone-dependent pathologies in the field of Women's Health. The company was founded in 1994 and is headquartered in Gosselies, Spain. | 25 years |
Christina Takke | M | 54 |
Syndesi Therapeutics SA
![]() Syndesi Therapeutics SA Miscellaneous Commercial ServicesCommercial Services Syndesi Therapeutics SA develops novel therapeutics for cognitive impairment which includes Alzheimer’s disease, dementias, and cognitive impairment associated with schizophrenia. The company is headquartered in Louvain-la-Neuve, Belgium. | - |
Jonathan R. Savidge | M | - |
Syndesi Therapeutics SA
![]() Syndesi Therapeutics SA Miscellaneous Commercial ServicesCommercial Services Syndesi Therapeutics SA develops novel therapeutics for cognitive impairment which includes Alzheimer’s disease, dementias, and cognitive impairment associated with schizophrenia. The company is headquartered in Louvain-la-Neuve, Belgium. | - |
Raf Moons | M | - |
Ogeda SA
![]() Ogeda SA Pharmaceuticals: MajorHealth Technology Ogeda SA discovers and develops small molecule drugs. It develops NK3 antagonists for the treatment of hormone-dependent pathologies in the field of Women's Health. The company was founded in 1994 and is headquartered in Gosselies, Spain. | - |
Melissa Israel | F | - | 4 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Piers John Morgan | M | 57 | 1 years | |
Jean-Luc Dimarcq | M | - |
Entomed SA
![]() Entomed SA Pharmaceuticals: MajorHealth Technology Entomed SA discovers and develops novel medicines derived from insects. It discovers and develops new drugs derived from the biology of insects with a focus on their immune response. Entomed's technology is based on the scientific work carried out by Prof. Jules A. Hoffmann's world leading team in the CNRS Institute of Molecular and Cellular Biology (IBMC) in Strasbourg. The company was founded in 1999 and is headquartered in Illkirch-Graffenstaden, France. | 7 years |
Peter Collum | M | - | 2 years | |
Adrian Hepner | M | 62 | 2 years | |
Marie Bouillez | F | 43 |
Epics Therapeutics SA
![]() Epics Therapeutics SA Miscellaneous Commercial ServicesCommercial Services EPICS Therapeutics SA engages in the development of therapeutic solutions for cancer. The company was founded by Jean Combalbert, Alain Parthoens and Francois Fuks on February 20, 2018 and is headquartered in Charleroi, Belgium. | - |
Rodolphe Hajj | M | - | 8 years | |
Alexandre Berda | M | - | 2 years |
Statistics
Country | Connections | % of total |
---|---|---|
Belgium | 23 | 74.19% |
France | 9 | 29.03% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Jean Combalbert
- Personal Network